| ●Editorial | Saio T | 194-5 | Full text | |
| ●Current status and challenges in pharmaceutical medicine | ||||
| Survey of Medical Affairs Activities (2023) and Future Challenges | Yamamoto T，Moritsugu Y， Tomiyasu M，Nishiuma S | 197-223 | Abstract | |
| An analysis of the current utilization of highly specialized professionals with advanced degrees sought by pharmaceutical companies and future outlook: Survey on recruitment and post-employment career support for physicians and PhD researchers in the pharmaceutical industry | Maeda-Chubachi T，Tamada H， Izutsu M，et al． |
225-38 | Abstract | |
| Learning pharmaceutical medicine together with patients and public | Imamura K | 239-44 | Abstract | |
| ●Evaluation of COVID-19 Vaccine Safety | ||||
| Aortic dissection following COVID-19 vaccination: A case study, analysis of voluntary death reports submitted to MHLW, and literature review | Hirai Y，Hikota H， Kikuchi T，et al． |
245-71 | Abstract | |
| Retraction unexplained: On the incomprehensive retraction by Cureus Editorial Board of “Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan”, a Japanese translation of which was published in Clinical Evaluation Vol. 52, No. 1. |
Editor-in-Chief, Clinical Evaluation | 273-5 | Full text | |
| Chronology of Events Surrounding the Publication and Retraction by Cureus Editorial Board of “Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan” doi: 10.7759/cureus.57860: Authors’ Testimony |
Miki Gibo，Seiji Kojima， Akinori Fujisawa，et al． |
|||
| ●Articles | ||||
| Occupational safety and health disparities: A review on their definitions and concepts |
Saio T | 277-86 | Full text | |
| Suicide-specific diagnostic categories: Focusing on suicidal behavior disorder, suicide crisis syndrome, and acute suicidal affective disturbance | Saio T | 287-300 | Abstract | |
| ●Translations and explanatory article | ||||
| Explanatory article on the guidance “Conducting Clinical TrialsWith Decentralized Elements Guidance for Industry, Investigators, and Other Interested Parties” |
Kurihara C，Matsuyama K | 301-4 | Full text | |
| Conducting Clinical Trials With Decentralized Elements Guidance for Industry, Investigators, and Other Interested Parties | U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research(CDER) Center for Biologics Evaluation and Research(CBER) Center for Devices and Radiological Health(CDRH) Oncology Center of Excellence(OCE) （Trans. by Kurihara C，Supervised by Matsuyama K） |
305-22 | ||
| Collaboration with the WMA and key contribution to the 2024 Revision of the Declaration of Helsinki |
Kurihara C，Matsuyama K，Baroutsou V （Trans. by Kurihara C，Matsuyama K） |
323-7 | Full text | |
| ●In Memorium | ||||
| The philosophies expressed by Dr. Masanao Kurihara, Editor-in-Chief of Clinical Evaluation, will be passed down to the next generation: “Fluctuat nec mergitur (Tossed by the waves, but does not sink)” | Tsubaki H | 329-32 | ||
| ●Instructions for authors［Japanese］＆［English］ | 333-41 | Full text | ||
| ●Editor’s note | Yamauchi K | 343 | Full text | |